BC-3402
- Generic Name
- BC-3402
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Hepato Cellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT06608940
- Locations
- 🇺🇸
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05970822
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath